JPS6027390A - Fr-900216 substance and its preparation - Google Patents

Fr-900216 substance and its preparation

Info

Publication number
JPS6027390A
JPS6027390A JP58133506A JP13350683A JPS6027390A JP S6027390 A JPS6027390 A JP S6027390A JP 58133506 A JP58133506 A JP 58133506A JP 13350683 A JP13350683 A JP 13350683A JP S6027390 A JPS6027390 A JP S6027390A
Authority
JP
Japan
Prior art keywords
reaction
substance
culture
soluble
chloroform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP58133506A
Other languages
Japanese (ja)
Other versions
JPH0434522B2 (en
Inventor
Masakuni Okuhara
奥原 正国
Hirokazu Tanaka
田中 洋和
Hideko Kino
木野 英子
Sumio Kiyotoo
清遠 純夫
Masanobu Kosaka
向阪 正信
Hatsuo Aoki
青木 初夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Priority to JP58133506A priority Critical patent/JPS6027390A/en
Priority to ZA845372A priority patent/ZA845372B/en
Priority to PH30984A priority patent/PH20405A/en
Priority to DK348784A priority patent/DK162631C/en
Priority to IE1832/84A priority patent/IE57748B1/en
Priority to US06/631,244 priority patent/US4680178A/en
Priority to DE8484108444T priority patent/DE3484155D1/en
Priority to EP84108444A priority patent/EP0132772B1/en
Priority to AU30853/84A priority patent/AU560728B2/en
Priority to IL72451A priority patent/IL72451A/en
Publication of JPS6027390A publication Critical patent/JPS6027390A/en
Publication of JPH0434522B2 publication Critical patent/JPH0434522B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

NEW MATERIAL:FR-900216 Substance having the following physical and chemical properties and its salt. Molecular weight: 625(mass spectrometry). Estimated molecular formula: C35H47NO9. Melting point: 130-135 deg.C(decomposition). Specific rotatory power: [alpha]D<20>=+140 deg.(C=1, in CHCl3). Solubility: easily soluble in methanol, acetone, ethyl acetate, soluble in chloroform and benzene, slightly soluble in hexane, ethyl ether, insoluble in water. Color reaction: positive in Dragendorff's reaction and iodine reaction, and negative in ferric chloride reaction, Molish reaction, etc. USE:An antitumor agent. PREPARATION:A fungus [e.g., Rhizopus sp. NO.F-1360(FERM-P 5362), etc.] belonging to the genus Rhizopus, capable of producing FR-900216 substance, is cultivated in a medium and the substance is collected and separated from the culture.

Description

【発明の詳細な説明】 この発明は優れた抗腫瘍作用を有する新規な物質である
FR−900216物質およびその製造法に関するもの
である。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel substance FR-900216 having excellent antitumor effects and a method for producing the same.

この発明のFR−900216物質の理化学的性質は次
の通りである。
The physicochemical properties of the FR-900216 substance of this invention are as follows.

■ 分子量: 62 s (マススペクト7し法)■ 
推定分子式:CHNO 5479 ■ 融 点:130−135℃(分解)■ 比旋光度°
〔α) −+140°(C=1゜クロロホルム中) ■ 紫外線吸収スペクトル: λCH30H= 232(E=11.3()O)、23
8(Sh、)。
■ Molecular weight: 62 s (mass spectrum 7 method) ■
Estimated molecular formula: CHNO 5479 ■ Melting point: 130-135℃ (decomposition) ■ Specific optical rotation °
[α) −+140° (C=1° in chloroform) ■ Ultraviolet absorption spectrum: λCH30H= 232 (E=11.3()O), 23
8 (Sh,).

ax 285(Sh 、 )、 296(ε=55,500)
 、 308(ε=70.300)、324(ε=51
,900)nm■ 赤外線吸収スペクトル: UKBr:3450.3140,2960,2920,
2860゜ax 17.30.1715(Sh、)、1607,1575
,1455゜1445.1435,137711360
,1343,1305゜1280.1260,1225
,1190,1170,1140゜1107.1077
.1045.1030(Sh、)、9’80゜970.
950,930,915,905,895.87!5゜
860.850,835,825,790,780,7
55゜705.670.63泊 ■ 水素の核磁気共鳴スペクトル: 図に示す通り(溶媒:重クロロホルム 内部標準:テト
ラメチルシラン) ■ 炭素13の核磁気共鳴スペクトル:(重クロロホル
ム中) 内部標準:テトラメチルシラン δ(ppm):9.65,11.41,11.71,1
3.77.14.32゜16.93 、22.57 、
29.24 、31.49 、31.85 、34.1
6 。
ax 285 (Sh, ), 296 (ε=55,500)
, 308 (ε=70.300), 324 (ε=51
,900)nm Infrared absorption spectrum: UKBr:3450.3140,2960,2920,
2860°ax 17.30.1715 (Sh,), 1607, 1575
,1455°1445.1435,137711360
,1343,1305°1280.1260,1225
,1190,1170,1140°1107.1077
.. 1045.1030 (Sh, ), 9'80°970.
950,930,915,905,895.87!5゜860.850,835,825,790,780,7
55°705.670.63 nights ■ Nuclear magnetic resonance spectrum of hydrogen: As shown in the figure (solvent: deuterated chloroform Internal standard: tetramethylsilane) ■ Nuclear magnetic resonance spectrum of carbon-13: (in deuterated chloroform) Internal standard: tetra Methylsilane δ (ppm): 9.65, 11.41, 11.71, 1
3.77.14.32゜16.93, 22.57,
29.24, 31.49, 31.85, 34.1
6.

35.86 、36.40 、37.98 、45.3
2 、54.18 、56.12 。
35.86, 36.40, 37.98, 45.3
2, 54.18, 56.12.

63.77.65.10,76.81,82.33,8
9.25,120.80゜123.77 、126.4
4 、129.29 、135.97 、136.21
 。
63.77.65.10, 76.81, 82.33, 8
9.25, 120.80°123.77, 126.4
4, 129.29, 135.97, 136.21
.

136.57 、137.67 、138.51 、1
39.54 、160.84 。
136.57 , 137.67 , 138.51 , 1
39.54, 160.84.

168.01.169.34 ■ 溶剤に対する溶解性: 易溶:メタノール、エタノール、アセトン、酢酸エチル 可溶:クロロホルム、ベンゼン 111(i :ヘキサン、エチルエーテル不溶:水 ■ 呈色反応: ドラゲンドルフ反応 士 塩化第2鉄反応 − モーリッシュ反応 − ニンヒドリフ反応 − エーリッヒ反応 − ヨード反応 十 ■ 塩基性、酸性、中性の区別; 弱塩基性 この発明のFR−900216物質は、例えばリゾプス
属に属するFR−900216物質生産菌のようなFR
−900216物質生産菌を培地に培養し、得られる培
養物からFR−900216物質を分離、採取すること
により製造することができる。この発明で使用するFR
−900216物質生産菌のうち、この発明者等が京都
府宇治市の土壌から新たに分離した菌株(A、F−13
60と番号を付す)は、次のような菌学的性質を有する
168.01.169.34 ■ Solubility in solvents: Easily soluble: methanol, ethanol, acetone, ethyl acetate Soluble: chloroform, benzene 111 (i: hexane, ethyl ether Insoluble: water ■ Color reaction: Dragendorff reaction, chloride Ferric reaction - Molisch reaction - Ninhydrif reaction - Ehrlich reaction - Iodo reaction FR like production bacteria
It can be produced by culturing -900216 substance-producing bacteria in a medium, and separating and collecting the FR-900216 substance from the resulting culture. FR used in this invention
-900216 substance-producing strains (A, F-13) newly isolated by the inventors from the soil of Uji City, Kyoto Prefecture.
No. 60) has the following mycological properties.

■ 形態学的性質 a)肉眼°的観察 1)麦芽エキス寒天培地上 生育は極めて旺盛で速く、30℃、3−5日間の培養で
直径80備以上の巨大集落を形成し、ベトリ皿を覆い尽
くす。集落表面は平坦で厚く、培養初期には白色である
が、胞子、胞子のうが形成され成熟するにつれて次第に
灰色ないし黒色となる。胞子のり、胞子は非常に多く形
成される。集落周辺部分はくもの巣状でベトリ皿や試験
管壁面迄付着して這い上がる。裏面の色は無色ないし薄
黄色。拡散性色素および浸出液は産出しない。芳香を放
つ。25℃ではやや生育が遅い。
■ Morphological Properties a) Macroscopic Observation 1) Growth on malt extract agar medium is extremely vigorous and fast, and after 3-5 days of culture at 30°C, huge colonies with a diameter of 80 mm or more are formed, covering the vetri dish. I will do my best. The colony surface is flat and thick, and is white at the initial stage of cultivation, but gradually becomes gray or black as spores and sporangia are formed and mature. Spore paste, spores are formed in large numbers. The area around the village is spider web-like and clings to the walls of beet dishes and test tubes and climbs up. The underside is colorless or pale yellow. No diffusible pigments or exudates are produced. Gives off a fragrance. Growth is somewhat slow at 25°C.

ii) Y、ss寒天培地上 麦芽エキス寒天培地と概ね同様である。ii) Y, on ss agar medium It is roughly the same as the malt extract agar medium.

l11)ポテト・グルコース寒天培地上麦芽エキス寒天
培地と概ね同様である。
l11) Potato glucose agar medium is generally similar to malt extract agar medium.

iv) ツアペック寒天培地上 はとんど生育しない。iv) On Czapek agar medium It rarely grows.

b)顕微鏡的観察 胞子のうば薄膜に包まれており、成熟すると袋が破れて
中の多数の胞子が弾は出る。胞子のうは直径30−20
0μ。球形。胞子は7.5×15μ″。楕円形で表面は
平滑、少ししわがある。基中菌糸は仮根(rhigoi
d)を形成し、分生子柄は互いにストロン(5tolo
n )で連結している。隔壁(5epta )6″l:
有しない。
b) Microscopic observation The spores are enclosed in a thin membrane, and when they mature, the bag ruptures and the many spores inside come out. Sporangium diameter 30-20
0μ. Spherical. The spores are 7.5 x 15μ''. Oval in shape with a smooth surface and a few wrinkles. The basal hyphae are rhizoids (rhigoi).
d), the conidiophores form stolons (5 tolo
n). Partition wall (5epta) 6″l:
I don't have it.

胞子のり柄の先端に柱軸(columella )を形
成する。
A columnar axis (columella) is formed at the tip of the spore stalk.

■ 生理的性質 a)生育温度範囲 40−48℃(ポテト・グルコース寒天培地上) 胞子のり着生14−39℃(同上培地)至適温度:33
℃(同上培地) b)ベラファー氏液(pfeffer 5olutio
n)で10℃では生育しない。25−42℃で生育する
■ Physiological properties a) Growth temperature range 40-48℃ (on potato glucose agar medium) Optimum temperature for spore attachment 14-39℃ (same medium): 33
°C (same medium) b) Pfeffer's solution (pfeffer 5 solution)
n) and does not grow at 10°C. Grows at 25-42°C.

C)生育pH範囲pT(2,5−12,0(麦芽汁およ
びys 寒天培地上) s d)有機酸を生産する。
C) Growth pH range pT (2,5-12,0 (on wort and ys agar) s d) Produce organic acids.

以上の実験結果より総合的に判断すると應F−1360
株は接合菌類Rh1zopus属の1菌種であると考え
られる。従って、この黒F−1360株をリゾプス・エ
スピーA F −1360(Rhizopus sp、
 /Ffi、F−1360)と命名した。
Judging comprehensively from the above experimental results, O F-1360
The strain is considered to be a species of the zygomycete Rh1zopus genus. Therefore, this black F-1360 strain was used as Rhizopus sp.
/Ffi, F-1360).

このリゾプス・エスピー/Ffi、F−1360はアメ
リカン・タイプ・カルチュア・コレクションに寄託番号
ATCCA、 20577として寄託されている。
This Rhizopus sp./Ffi, F-1360, has been deposited with the American Type Culture Collection under deposit number ATCCA, 20577.

また、このリゾプス・エスピーA、F −13601d
Also, this Rhizopus sp. A, F-13601d
.

工業技術院微生物工業技術研究所に微工研菌寄第536
2号として寄託されている。
Microbiological Research Institute No. 536 at the Institute of Microbial Technology, Agency of Industrial Science and Technology
It has been deposited as No. 2.

この発明で使用するFR−900216物質生産菌、例
えばリゾプス属に属するF R−900216物質生産
菌は、例えばX線、紫外線などの照射処理、例エハナイ
トロジェン・マスタードごアザセリン、亜硝酸、2−ア
ミノプリン、N−メチル−N′−ニトロ−N−ニトロソ
グアニジン(NTG)などの変異誘起剤による処理、フ
ァージ接触、形質転換、形質導入、接合などの通常用い
られる菌株変異処理方法により、FR−900216物
質の生産能を高めることができる。
The FR-900216 substance-producing bacteria used in this invention, for example, the FR-900216 substance-producing bacteria belonging to the genus Rhizopus, can be treated with irradiation such as X-rays and ultraviolet rays, such as nitrogen, mustard, azaserine, nitrous acid, 2- FR- The production capacity of 900216 substance can be increased.

リゾプス属に属するFR−900216物質の生産菌を
培地に培養することにより行なわれるFR−90021
6物質の生産は原則的には一般微生物の培養方法に準す
るが、通常は液体培地による深部培養法が有利である。
FR-90021 is carried out by culturing in a medium a producing bacterium of the FR-900216 substance belonging to the genus Rhizopus.
The production of the six substances basically follows the cultivation method of general microorganisms, but the deep culture method using a liquid medium is usually advantageous.

培地に用いられる培地としては、リゾプス属に属するF
R−900216物質生産菌が利用する栄養源を含有す
る培地であれば占い。すなわち、合成培地、半合成培地
あるいは天然培地が用いられ、培地組成は炭素源としテ
ハ、例エバグルコース、シュークロース、マルトース、
グリセリン、でん粉、液化でん粉等が用いられ、窒素源
として、例えば肉エキス、カゼイン加水分解物、ペプト
ン、グルテンミール、コーンミール、#ill実粕、大
豆粉、コーンスチープリカー、乾燥酵母、酵母エキス、
尿素、りん酸アンモニウム等が用いられる。このほか、
例えばりん酸水素2ナトリウム、りん酸2水素カリウム
、塩化マグネシウム、硫酸マグネシウム、炭酸カルシウ
ム等の無機塩も必要に応じて培地に添加される。
The medium used for the culture medium is F, which belongs to the genus Rhizopus.
Fortune-telling if the medium contains a nutrient source used by R-900216 substance-producing bacteria. That is, a synthetic medium, a semi-synthetic medium, or a natural medium is used, and the medium composition includes carbon sources such as evaglucose, sucrose, maltose,
Glycerin, starch, liquefied starch, etc. are used, and as nitrogen sources, for example, meat extract, casein hydrolyzate, peptone, gluten meal, corn meal, #ill grain meal, soybean flour, corn steep liquor, dried yeast, yeast extract,
Urea, ammonium phosphate, etc. are used. other than this,
For example, inorganic salts such as disodium hydrogen phosphate, potassium dihydrogen phosphate, magnesium chloride, magnesium sulfate, and calcium carbonate are also added to the medium as necessary.

1だ、培養中発泡の著しい時には、例えば大豆油、亜麻
仁油等の植物油、オクタデカノール、テトラデカノール
、ヘプタノ−1し等の高級アルコール類、シリコン化合
物等の消泡剤を適宜添加すればよい。
1. If there is significant foaming during culture, add antifoaming agents such as vegetable oils such as soybean oil and linseed oil, higher alcohols such as octadecanol, tetradecanol, and heptano-1, and silicon compounds as appropriate. good.

培養温度は30℃前後が適当であり、培養容量の増大に
従って適宜種培養を行なうと好結果が得られることが多
い。本培養の培養時間は50〜100時間位が適当であ
り、培地が濃厚になるのに従って、培養時間をさらに延
長してもよい。
A suitable culture temperature is around 30°C, and good results are often obtained by carrying out seed culture as appropriate as the culture volume increases. The culture time for the main culture is suitably about 50 to 100 hours, and the culture time may be further extended as the medium becomes more concentrated.

以上述べた培養条件は使用生産菌株の特性に応じてそれ
ぞれの最適の条件を選択して適用される。
The culture conditions described above are applied by selecting the optimum conditions for each depending on the characteristics of the production strain used.

次に、培養により生成したFR−900216物質は通
常、培養物中の菌体内および菌体外の両方に蓄積される
ことが多いので、一般には遠心分離、ろ過等の手段によ
り、菌体およびろ液(上澄液)に分離した後双方から一
般抗生物質の製造に用いられる手段により分離、精製お
よび採取される。すなわち、通常、菌体内の目的物質は
溶媒抽出等の抽出手段により菌体から分離抽出される。
Next, since the FR-900216 substance produced by culture usually accumulates both inside and outside of the bacterial cells in the culture, it is generally necessary to remove the bacterial cells and the filter by means such as centrifugation or filtration. After separating into a liquid (supernatant), both are separated, purified, and collected by means used in the production of general antibiotics. That is, the target substance within the bacterial cells is usually separated and extracted from the bacterial cells by extraction means such as solvent extraction.

そしてこの抽出物および上記ろ2(上澄液)に減圧濃縮
、溶媒抽出、液性変換、例えば陰イオン交換樹脂、陽イ
オン交換樹脂、非イオン性吸着樹脂等の樹脂による処理
、例えば活性炭、けい酸、シリカゲル、アルミナ、セル
ロース等の吸着剤による処理、結晶化、再結晶等の手段
を任意の順序に組合せ捷たは反復して適用することによ
り、目的物質、FR−900216物質を分離、精製す
ることができる。
This extract and the above-mentioned filtration 2 (supernatant liquid) are subjected to vacuum concentration, solvent extraction, liquid conversion, treatment with resins such as anion exchange resins, cation exchange resins, and nonionic adsorption resins, such as activated carbon, silica, etc. Separate and purify the target substance, FR-900216 substance, by combining or repeatedly applying methods such as treatment with adsorbents such as acid, silica gel, alumina, and cellulose, crystallization, and recrystallization in any order. can do.

壕だ、このようにして得られたFR−900216物質
を常法により処理することによってその医薬として許容
され得る塩を得ることができる。
However, the FR-900216 substance thus obtained can be treated in a conventional manner to obtain its pharmaceutically acceptable salt.

そのようなFR−900216物質の医薬として許容さ
れ得る塩としては例えば無機もしくは有機酸との酸付加
塩(例えば、酢酸塩、乳酸塩、マレイン酸塩、フマール
酸塩、修酸塩、くえん酸塩、メタンスルホン酸塩、塩酸
塩、硫酸塩、硝酸塩、りん酸塩等)等が挙げられる。
Pharmaceutically acceptable salts of such FR-900216 substances include, for example, acid addition salts with inorganic or organic acids (e.g., acetates, lactates, maleates, fumarates, oxalates, citrates). , methanesulfonate, hydrochloride, sulfate, nitrate, phosphate, etc.).

次にこの発明のFR−900216物質の生物学的性質
を示す。
Next, the biological properties of the FR-900216 substance of this invention will be shown.

試験例1 マウス白血病L1210およびP2S5に対
する抗腫瘍作用 試験法 マウス白血病L1210およびP2S5をそれぞれD 
B A / 2マウスに継代移植し移植後7日目の腹腔
より腹水を採取し、その腫瘍細胞を分離し、さらに細胞
数を調整し、細胞浮遊液とした。その浮遊液の0.2m
/(L1210では105細胞、P2S5では106細
胞)をBDF1マウス(L1210の実験では、体重1
7.9−21.79の7週令雌、P2S5の実験では体
重18.4−22.59の8週令雌)の腹腔内に移植し
た。FR−900216物質はメタノールに溶解した後
濃縮し、濃縮物を水に溶解して水溶液とし、所定量1日
1回4日間上記の腫瘍細胞を移植したマウスの腹腔内に
投与した。抗腫瘍活性は各群の平均生存日数(1)の対
照群の平均生存日数(C)に対する百分率(T/CX1
00)で示した。
Test Example 1 Antitumor effect test method for murine leukemia L1210 and P2S5.
The tumor cells were subcultured into B A/2 mice, and ascitic fluid was collected from the peritoneal cavity on the 7th day after transplantation, the tumor cells were separated, and the number of cells was adjusted to prepare a cell suspension. 0.2m of the floating liquid
/ (105 cells for L1210, 106 cells for P2S5) in BDF1 mice (1 body weight for L1210 experiments)
It was transplanted intraperitoneally into a 7-week-old female weighing 7.9-21.79 mm (in the P2S5 experiment, an 8-week-old female weighing 18.4-22.59 mm). The FR-900216 substance was dissolved in methanol and then concentrated, and the concentrate was dissolved in water to obtain an aqueous solution, and a predetermined amount was intraperitoneally administered once a day for 4 days to mice implanted with the above tumor cells. The antitumor activity is expressed as a percentage of the average survival days (1) of each group to the average survival days (C) of the control group (T/CX1
00).

結果 表1に示した。result It is shown in Table 1.

(以下余白) 試験例2 マウス メラノーマB16に対する抗腫瘍作
用 試験法 マウスメラノーマB16iDBA/2マウスに継代移植
し、移植後14日口の皮下より腫瘍を無菌的に採取し、
その1gをハンクス液10耐に混合シ、ホモジナイズし
た。この0.5 */ f B D F 1マウス(体
重19.7−24.89の12週令雌)の物質の水溶液
の所定量を1日1回4日間腹腔内に投与した。抗腫瘍活
性は試験例1と同様に算出した。
(Margins below) Test Example 2 Test method for antitumor effect on mouse melanoma B16 Mouse melanoma B16 was subcutaneously transplanted into mice, and 14 days after transplantation, the tumor was aseptically collected subcutaneously from the mouth.
1 g of the mixture was mixed with Hank's solution 10 resistant and homogenized. A predetermined amount of the aqueous solution of the substance was administered intraperitoneally once a day for 4 days to 0.5*/f BD F 1 mice (12-week-old females weighing 19.7-24.89 kg). Antitumor activity was calculated in the same manner as in Test Example 1.

結果 表2に示した。result It is shown in Table 2.

(以下余白) このようにこの発明のFR−900216物質およびそ
の医薬として許容され得る塩は抗腫瘍作用を有し、医薬
として有用である。
(Left below) As described above, the FR-900216 substance of the present invention and its pharmaceutically acceptable salts have antitumor effects and are useful as medicines.

この発明の目的化合物であるFR−900216物質ま
たはその医薬として許容され得る塩を腫瘍の治療目的で
投与するに当っては、FR−900216物質を有効成
分とし、これに医薬上許容される担体、例えば経口もし
くは非経口の有機もしぐは無機、固体または液体の賦形
剤を加えた製剤の形で使用できる。このような製剤とし
ては、カプセル、錠剤、顆粒剤などの固体製剤および液
剤、けんだく剤、乳剤などの液体製剤のほか坐剤などが
含まれる。さらに必要に応じて前記製剤中に補助剤、安
定剤、湿潤剤、乳化剤、緩衝剤、その他繁用される添加
剤を含有させることができる。
When administering the object compound of this invention, FR-900216 substance or a pharmaceutically acceptable salt thereof, for the purpose of tumor treatment, the FR-900216 substance is used as an active ingredient, and a pharmaceutically acceptable carrier, For example, oral or parenteral organic medicines can be used in the form of preparations with inorganic, solid or liquid excipients. Such preparations include solid preparations such as capsules, tablets, and granules, liquid preparations such as solutions, suspensions, and emulsions, as well as suppositories. Furthermore, if necessary, adjuvants, stabilizers, wetting agents, emulsifiers, buffers, and other frequently used additives can be included in the preparation.

FR−900216物質またはその医薬として許容し得
る塩の投与量は患者の年令、状態、疾病の種類および病
状により異なるが、この発明の化合物を平均1回につき
、約1001f、200ダ、400■または1,600
#の量を投与すれば、腫瘍の治療に有効である。一般に
FR−900216物質またはその医薬として許容し得
る塩は1日当り約200岬ないし4,0OOW場合によ
ってはそれ以上の量で投与することができる。
The dosage of the FR-900216 substance or its pharmaceutically acceptable salt varies depending on the patient's age, condition, type of disease, and medical condition, but the average dose of the compound of this invention per dose is about 1001f, 200dah, 400dah. or 1,600
If administered in an amount of #, it is effective in treating tumors. Generally, the FR-900216 substance, or a pharmaceutically acceptable salt thereof, can be administered in an amount of about 200 to 4,000 OOW per day, and in some cases more.

次に実施例に基づいてこの発明を説明する。Next, the present invention will be explained based on examples.

実施例1 コーンスターチ1%、グルコース0.5%、クルテンミ
ール1%、乾燥酵母1%、コーンスターデリカ−1%の
組成の培地(滅菌前pH7,0)を275 m/容広n
エルレンマイヤーフラスコ6本にそれぞれ80耐ずつ分
注し、120℃で30分間げ 滅菌する。これらにリゾプス・ニスK −S、 F −
1360の斜面培養物をそれぞれ1白金耳ずつ接種L、
ロータリーシエイカーで毎分250回転、30℃で48
時間培養を行う。別に可溶性でん粉2%、グリセリン0
.5%、グルコース0.5%、グルテンミール1%、乾
燥酵母1%、コーンスターブリカー1%の組成の培地(
pH7,0) 201!を301!容ジャーファーメン
タ−に注入し、120℃で30分間滅菌する。次いで、
これに上記培養物の全量を接種し、通気量IVVM、撹
拌速度撹拌速度毎分20焙 これを種培養とする。
Example 1 A medium (pH 7.0 before sterilization) with the composition of 1% corn starch, 0.5% glucose, 1% corn starch meal, 1% dried yeast, and 1% corn starch was grown at 275 m/volume n.
Dispense 80ml each into 6 Erlenmeyer flasks and sterilize by boiling at 120°C for 30 minutes. These include Rhizopus varnish K-S, F-
1 loop of each slant culture of 1360 was inoculated with L;
Rotary shaker at 250 revolutions per minute and 48°C at 30℃
Perform time culture. 2% soluble starch, 0 glycerin
.. 5%, glucose 0.5%, gluten meal 1%, dry yeast 1%, corn starch liquor 1% (
pH7,0) 201! 301! Pour into a jar fermenter and sterilize at 120°C for 30 minutes. Then,
The entire amount of the above culture was inoculated into this, and the aeration amount was IVVM and the stirring speed was 20 per minute.This was used as a seed culture.

さらに、可溶性でん粉2%、グリセリン0.5%、乾燥
酵母1%、綿実粕1%、大豆粉0.5%、炭酸カルシウ
ム1%の組成の培地(pH7、0)1501f2 0 
01!容ジャーファーメンタ−に注入し、120℃で3
0分間滅菌する。これに上記種培養物81!を接種し、
通気量0. 7 VVM 、撹拌速度毎分250回転、
培養温度3otで72時間培養する。培養終了後、培養
物にけい藻土5kgを加えてろ過する。得られた菌体を
含むケーキに酢酸エチlし801!を加えて撹拌し、次
いで酢酸エチル層を分取する。この菌体からの有効成分
の抽出操作を再度くり返し、得られた酢酸エチル抽出物
をII!1で減圧濃縮する。濃縮物を0.5%重曹水−
00耐で洗浄して酢酸エチル層を分取する。この酢酸エ
チルmt無水硫酸ナトリウムで脱水し3 0 0 ml
葦で濃縮する。この濃縮物全シリカゲルクロマトグラフ
ィー(シリカゲル:2500II/)に付し、クロロホ
ルムでカラムを洗浄後、クロロホルムとメタノールの混
液(100:1)で溶出する。
Furthermore, a medium (pH 7, 0) with a composition of 2% soluble starch, 0.5% glycerin, 1% dry yeast, 1% cottonseed meal, 0.5% soybean flour, and 1% calcium carbonate 1501f2 0
01! Pour into a jar fermenter and heat at 120℃ for 3 hours.
Sterilize for 0 minutes. Add to this the above seed culture 81! inoculate with
Airflow amount 0. 7 VVM, stirring speed 250 revolutions per minute,
Culture at a culture temperature of 3 ot for 72 hours. After culturing, 5 kg of diatomaceous earth is added to the culture and filtered. Add ethyl acetate to the cake containing the obtained bacterial cells and 801! was added and stirred, and then the ethyl acetate layer was separated. This procedure for extracting the active ingredients from the bacterial cells is repeated again, and the obtained ethyl acetate extract is used as II! Concentrate under reduced pressure in Step 1. Concentrate with 0.5% sodium bicarbonate water
Wash with 00 resistance and separate the ethyl acetate layer. This ethyl acetate mt was dehydrated with anhydrous sodium sulfate to 300 ml.
Concentrate with reeds. This concentrate was subjected to total silica gel chromatography (silica gel: 2500 II/), and after washing the column with chloroform, it was eluted with a mixture of chloroform and methanol (100:1).

目的物を含むクロロホルムメタノール溶出画分(1(R
)を減圧濃縮し、約20g/にまで濃縮しヘキサン1.
54’を加えて、得られる沈殿をろ過して集め、乾燥し
て目的物を含む和粉末11すを得る。この粗粉末を10
0g+/のメタノ−7しに溶解してNSゲV(日本精密
化学社製)を用いた逆相クロマトグラフィー(NSゲル
:1500禦l)に付し、メタノールで溶出し細かく分
画する。目的物を含む溶出画分(800y/)を減圧濃
縮し、約10胃/にまで濃縮しヘキサンIl!を加えて
、得られる沈殿をろ過して集め、粉末630qi得る。
Chloroform methanol elution fraction (1 (R
) was concentrated under reduced pressure to about 20 g/hexane.
54' is added, and the resulting precipitate is collected by filtration and dried to obtain 11 pieces of Japanese powder containing the target product. 10 pieces of this coarse powder
The solution was dissolved in 0 g+/ of methanol-7 and subjected to reverse phase chromatography (NS gel: 1500 mm) using NS Gel V (manufactured by Nippon Seikagaku Co., Ltd.), and finely fractionated by elution with methanol. The eluted fraction (800y/) containing the target product was concentrated under reduced pressure to about 10 y/ml and added to hexane Il! and collect the resulting precipitate by filtration to obtain 630 qi of powder.

この粉末をシリカゲル薄層クロマトグラフィーに付シ、
クロロホルムとメタノールの混液( 2 0 :1)で
展開し、目的物を含む両分をかきとってクロロホルムメ
タノール混液(10:1)で溶出する。溶出液8(1+
tを減圧濃縮し約5耐にまで濃縮してヘキサン5 0 
0 mlを加えて得られる沈殿をろ過して集め、FR−
900216物質の白色粉末300gjlを得る。
This powder was subjected to silica gel thin layer chromatography.
Develop with a mixture of chloroform and methanol (20:1), scrape off both parts containing the target substance, and elute with a mixture of chloroform and methanol (10:1). Eluate 8 (1+
Concentrate t under reduced pressure to about 50% hexane.
The precipitate obtained by adding 0 ml was collected by filtration and FR-
300 gjl of white powder of substance 900216 is obtained.

元素分析値(へ): C66、30 、H7.61 、
N2.18実施例2 コーンスターチ1%,グルコース0.5%,クルテンミ
ール1%. 乾燥酵fB t%,コーンスタープリ力−
1%の組成の培地(滅菌前pH7.0)i2 7 5 
1t/容広ロ工ルレンマイヤーフラスコ6本にそれぞれ
Bowlずつ分注し、120℃で30分間滅菌する。こ
れらにリゾプス・エスピーAF −1 360の斜面培
養物をそれぞれ1白金耳ずつ接種し、ロータリーシェイ
カーで毎分250回転、30℃で48時間培養を行う。
Elemental analysis value (to): C66,30, H7.61,
N2.18 Example 2 Corn starch 1%, glucose 0.5%, gluten meal 1%. Dry fermentation fB t%, cornstarch power
Medium composition of 1% (pH 7.0 before sterilization) i2 7 5
Dispense each bowl into 6 1 ton/Rollenmeyer flasks and sterilize at 120°C for 30 minutes. One platinum loop of Rhizopus sp. AF-1 360 slant culture was inoculated into each of these, and cultured at 30° C. for 48 hours at 250 revolutions per minute in a rotary shaker.

別に可溶性でん粉2%、グリセリン1%、グルコース0
.5%、グルテンミール1%, 乾燥酵FRt%,コー
ンスチープリ力−1%の組成の培地(pH7.0)2(
ll!を301!容シャーファーメンタ−に注入し、1
20℃200回転、培養温度30℃で24時間培養しこ
れを種培養とする。
Separately 2% soluble starch, 1% glycerin, 0 glucose
.. 5%, gluten meal 1%, dry fermentation FRt%, corn steeple strength -1% (pH 7.0) 2 (
ll! 301! Inject into Schafer Mentor, 1
Cultivate for 24 hours at 20°C, 200 rotations, and culture temperature of 30°C, and use this as a seed culture.

さらに可溶性でん粉2%、グリセリン1%、乾燥酵母1
%、綿実粕1%、大豆粉0.5%、炭酸カルシウム1%
の組成の培地(pH7.o)xso./’i2 0 0
1!容ジャーファーメンタ−に注入し、120℃で30
分間滅菌する。これに上記種培養物81!を接種し、通
気量0, 7 VVM,撹拌速度毎分250回転、培養
温度3 0 ”Cで72時間培養する。
In addition, 2% soluble starch, 1% glycerin, and 1% dry yeast.
%, cottonseed meal 1%, soybean flour 0.5%, calcium carbonate 1%
A medium with the composition (pH 7.o) xso. /'i2 0 0
1! Pour into a jar fermenter and heat at 120℃ for 30 minutes.
Sterilize for minutes. Add to this the above seed culture 81! was inoculated and cultured for 72 hours at an aeration rate of 0.7 VVM, a stirring speed of 250 revolutions per minute, and a culture temperature of 30''C.

培養終了後、培養物にけい藻±5kgを加えてろ過する
。得られた菌体を含むケーキに酢酸エチルgo7’l加
え、撹拌した後濾過する。この操作を再度くり返し、得
られた酢酸エチル抽出物を1!!1で減圧濃縮する。濃
縮物を0.5%重曹水500w1で洗浄して酢酸エチル
層を分取する。この酢酸エチル層を無水硫酸かトリウム
で脱水し3 0 0 xtt寸で濃縮する。この濃縮物
をシリカゲルカラムクロマトグラフィー(シリカゲル:
2500譚/)に付し、クロロホルムでカラムを洗浄後
、クロロポルムとメタノールの混液(100:1)で溶
出する。目的物を含むクロロホルムメタノール溶出画分
( 1 0.、J )を減圧濃縮し、約5o耐に1で濃
縮しヘキサン2Jk加えて、得られる沈殿をろ過して集
め、乾燥して目的物を含む粗粉末2.59f得る。この
粗粉末を大量分取用高速液体クロマトグラフ6日本ウォ
ーターズリミテッド社製、使用カラムはプレパック50
 o/シリカ)にかけてクロロホルム−メタノールの混
液(100:1.5)の溶媒系を用いて活性画分を得る
。得られた活性画分を減圧濃縮し、ヘキサン100+l
を加えて、得られる沈殿をろ過して集め、乾燥して粉末
1.29を得る。この粉末を再び同一条件で大量分取用
高速液体クロマトグラフにかけて同一処理をおこ々うと
FR−900216物質の白色粉末500Mgを得る。
After culturing, ±5 kg of diatoms is added to the culture and filtered. Go7'l of ethyl acetate is added to the resulting cake containing bacterial cells, stirred, and then filtered. This operation was repeated again, and the obtained ethyl acetate extract was added to 1! ! Concentrate under reduced pressure in Step 1. The concentrate was washed with 500w1 of 0.5% sodium bicarbonate solution, and the ethyl acetate layer was separated. This ethyl acetate layer is dehydrated with anhydrous sulfuric acid or thorium and concentrated to a size of 300 x tt. This concentrate was subjected to silica gel column chromatography (silica gel:
After washing the column with chloroform, the column was eluted with a mixture of chloroporum and methanol (100:1). Concentrate the chloroform-methanol elution fraction (10., J) containing the target product under reduced pressure, concentrate at 1 to about 5°C, add 2Jk of hexane, collect the resulting precipitate by filtration, and dry it to contain the target product. 2.59f of coarse powder is obtained. This coarse powder was collected using a high-performance liquid chromatograph 6 manufactured by Nippon Waters Limited, and the column used was Prepack 50.
The active fraction is obtained using a solvent system of chloroform-methanol mixture (100:1.5). The obtained active fraction was concentrated under reduced pressure and added with 100+ liters of hexane.
The resulting precipitate is collected by filtration and dried to obtain powder 1.29. This powder was again subjected to the same treatment using a high-performance liquid chromatograph for mass preparative use under the same conditions to obtain 500 Mg of white powder of the FR-900216 substance.

【図面の簡単な説明】[Brief explanation of drawings]

図面はこの発明で得られるFR−900216物質の水
素の核磁気共鳴吸収スペクトルを示す。 出願人 藤沢薬品工業株式会社
The drawing shows the hydrogen nuclear magnetic resonance absorption spectrum of the FR-900216 material obtained by the present invention. Applicant Fujisawa Pharmaceutical Co., Ltd.

Claims (1)

【特許請求の範囲】 (11次の即化学的性質を有するFR−900216物
質およびその医薬として許容され得る塩。 ■ 分子量: 625 (マススペクトル法)■ 推定
分子式;C35H47NO9 ■ 副1 点 130−135℃(分解)■ 比旋光度
: (a′:J、o=+ 140’ (C−1。 クロロホルム中) ■ 紫外線吸収スペクトル: λCH30H−232(ε=11,300) 、 23
8(Sh、) 。 ax 285(Sh、)、296(ε=55,500 )、 
308(ε=70.300)、324(ε=51,90
0)nm■ 赤外線吸収スペクトル: Br υmax + 3450.3140,2960,292
0,2860゜茹R乎、14jb、1j77.1360
,1343,1305゜1280.1260.−122
5.1190,1170,1140゜11071107
7.1045,1030(Sh、)、980゜970.
950,930,915,905,895,875゜8
60.850,835,825,790,780,75
5゜1 7(15,670,6350I! ■ 水素の核磁気共鳴スペクトル;図に示す通り(溶媒
:市りロロホlレム、内部!準:テトラメチルシラン) ■ 次素13の核磁気共鳴スペクトlし;(溶媒′重り
ロロホ7レム、内部標準゛テトラメチルシラン) δ(ppm)=9.65,11.41,11.71,1
3.77.14.32゜16.93 、22.57 、
29.24 、31.49 、31.85 、34.1
(i 。 35.86,36.40,37.9B、45.32,5
4.18,56.12゜63.77 、65.10 、
76.81 、82.33 、89.25 。 120.80 、123.77 、126.44 、1
29:29 、135.97 。 136.21 、136.57 、137.67 、1
38.51 、139.54 。 160.84 、168.01 、169.34■ 溶
剤に対する溶解性 易溶:メタノール、エタノール、アセトン、酢酸エチル 可溶:クロロホルム、ベンゼン 難溶:ヘキサン、エチルエーテル 不溶:水 ■ 呈色反応: ドラゲンド!レフ反応 十 惧 圀化第2鉄反応 − モーリッシュ反応 − ニンヒドリン反応 − 工−リソヒ反応 − ヨード反応 十 ■ 塩基性、酸性、中性の区別: 弱塩基性 (2) リゾプス属に属するFR−900216物質生
産菌を培地に培養し、得られる培養物からFR−900
216物質を分離、採取することを特徴とするFR−9
00216物質の製造法。
[Claims] (FR-900216 substance having the 11th order immediate chemical properties and its pharmaceutically acceptable salt. ■ Molecular weight: 625 (mass spectrometry) ■ Estimated molecular formula; C35H47NO9 ■ Sub 1 point 130-135 °C (decomposition) ■ Specific optical rotation: (a': J, o = + 140' (C-1. in chloroform) ■ Ultraviolet absorption spectrum: λCH30H-232 (ε = 11,300), 23
8 (Sh,). ax 285 (Sh, ), 296 (ε=55,500),
308 (ε=70.300), 324 (ε=51,90
0) nm ■ Infrared absorption spectrum: Br υmax + 3450.3140, 2960, 292
0,2860゜boiled R乎, 14jb, 1j77.1360
,1343,1305°1280.1260. -122
5.1190,1170,1140°11071107
7.1045,1030 (Sh,), 980°970.
950,930,915,905,895,875゜8
60.850,835,825,790,780,75
5゜1 7 (15,670,6350I! ■ Nuclear magnetic resonance spectrum of hydrogen; as shown in the figure (solvent: hydrogen, internal! quasi: tetramethylsilane) ■ Nuclear magnetic resonance spectrum of the next element 13 l (Solvent weight: 7 rem, internal standard: tetramethylsilane) δ (ppm) = 9.65, 11.41, 11.71, 1
3.77.14.32゜16.93, 22.57,
29.24, 31.49, 31.85, 34.1
(i. 35.86, 36.40, 37.9B, 45.32, 5
4.18, 56.12゜63.77, 65.10,
76.81, 82.33, 89.25. 120.80, 123.77, 126.44, 1
29:29, 135.97. 136.21 , 136.57 , 137.67 , 1
38.51, 139.54. 160.84, 168.01, 169.34 ■ Solubility in solvents Easy soluble: methanol, ethanol, acetone, ethyl acetate Soluble: chloroform, benzene Slightly soluble: hexane, ethyl ether Insoluble: water ■ Color reaction: Dragend! Lef reaction Ferric reaction - Molisch reaction - Ninhydrin reaction - Ko-Risohi reaction - Iodine reaction 10 ■ Distinction between basic, acidic and neutral: Weak basic (2) FR-900216 belonging to the genus Rhizopus FR-900 is obtained from the culture obtained by culturing the substance-producing bacteria in a medium.
FR-9 is characterized by separating and collecting 216 substances.
00216 Method for producing substance.
JP58133506A 1983-07-21 1983-07-21 Fr-900216 substance and its preparation Granted JPS6027390A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP58133506A JPS6027390A (en) 1983-07-21 1983-07-21 Fr-900216 substance and its preparation
ZA845372A ZA845372B (en) 1983-07-21 1984-07-11 Antitumor agent
PH30984A PH20405A (en) 1983-07-21 1984-07-13 Anti-tumor agent container fr.900216 substance or its pharmaceutically acceptable salts thereof
DK348784A DK162631C (en) 1983-07-21 1984-07-16 COMPOUND, designated FR-900216, FOR USE AS THERAPEUTIC ACTIVE SUBSTANCE, PHARMACEUTICAL PREPARATION CONTAINING THE COMPOUND AND USING THE COMPOUND
IE1832/84A IE57748B1 (en) 1983-07-21 1984-07-16 Fr-900216 substance obtainable by cultivating atcc 20577 for use as an active therapeutic substance and pharmaceutical antitumor composition comprising fr-900216 substance
US06/631,244 US4680178A (en) 1983-07-21 1984-07-16 Antitumor agent comprising FR-900216
DE8484108444T DE3484155D1 (en) 1983-07-21 1984-07-18 FR-900216 COMPONENT, OBTAINED BY CULTIVATING ATCC 20577, USED AS ACTIVE THERAPEUTIC COMPOUND, AND ANTITUMORAL PHARMACEUTICAL COMPOSITION CONTAINING IT.
EP84108444A EP0132772B1 (en) 1983-07-21 1984-07-18 Fr-900216 substance obtainable by cultivating atcc 20577 for use as an active therapeutic substance and pharmaceutical antitumor composition comprising fr-900216 substance
AU30853/84A AU560728B2 (en) 1983-07-21 1984-07-19 Fr-900216 (rhizoxin)
IL72451A IL72451A (en) 1983-07-21 1984-07-19 Pharmaceutical antitumor composition containing rhizoxin and method for the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58133506A JPS6027390A (en) 1983-07-21 1983-07-21 Fr-900216 substance and its preparation

Publications (2)

Publication Number Publication Date
JPS6027390A true JPS6027390A (en) 1985-02-12
JPH0434522B2 JPH0434522B2 (en) 1992-06-08

Family

ID=15106361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58133506A Granted JPS6027390A (en) 1983-07-21 1983-07-21 Fr-900216 substance and its preparation

Country Status (2)

Country Link
JP (1) JPS6027390A (en)
ZA (1) ZA845372B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6084220A (en) * 1983-10-17 1985-05-13 Norin Suisansyo Nogyo Kankyo Gijutsu Kenkyusho Antitumor agent containing phizoxin which is metabolite of plant pathogenic germ phizopus chinensis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6084220A (en) * 1983-10-17 1985-05-13 Norin Suisansyo Nogyo Kankyo Gijutsu Kenkyusho Antitumor agent containing phizoxin which is metabolite of plant pathogenic germ phizopus chinensis

Also Published As

Publication number Publication date
JPH0434522B2 (en) 1992-06-08
ZA845372B (en) 1985-02-27

Similar Documents

Publication Publication Date Title
KR0135600B1 (en) Anticancer antibiotic mi43-37f11
JPS6016236B2 (en) Production method of antibiotic C-15003 P-3
JPH04352783A (en) 12-membered ring macrolide compound
JPS61148189A (en) Cl-1577d and cl-1577e antibiotic/antitumoral compounds and manufacture
JPS6027390A (en) Fr-900216 substance and its preparation
JPH03141290A (en) Antitumor antibiotic bmy-41339
JP3641050B2 (en) Novel physiologically active substance K93-0711 I-1 and I-2 and process for producing them
JPS6015318B2 (en) New antibiotic SF-1942 substance, its manufacturing method and anticancer agent containing it
JPS6219599A (en) Novel macrolide antibiotic m119
JPH041179A (en) Antitumor substance be-14106
JPH07278041A (en) Antitumor substance be-24811 and its production
JP2594085B2 (en) SF2575, a new antitumor antibiotic, and method for producing the same
JP2000086627A (en) Antibacterial substance be-54476 and its production
JPS61151149A (en) Differanisole a and its preparation
JPS623789A (en) Antibiotic substance tokimycin a and production thereof
JPS62434A (en) Novel compound ss7313a, production thereof and immunological regulator containing said compound
JPH0259596A (en) Novel substance, utilization and production thereof
JPH02275893A (en) Macrolide-based compound
JPH04108787A (en) New 18-membered macrolide compound
JPH0314588A (en) Physiologically active compound 3822a and b
JPH0725878A (en) Platelet aggregation inhibitor pi-334
JPH0449291A (en) Bioactive substance fd-891
JPS58319B2 (en) New antibiotic SF-1917 substance and its manufacturing method
JPH03279379A (en) New compound indanonaphthol a and b
JPH08325284A (en) New substance for attenuating il-6 activity as chlovalicin and its production